Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy

Motoko Yamaguchi, Katsuyoshi Takata, Tadashi Yoshino, Naoki Ishizuka, Masahiko Oguchi, Yukio Kobayashi, Yasushi Isobe, Kenichi Ishizawa, Nobuko Kubota, Kuniaki Itoh, Noriko Usui, Kana Miyazaki, Izumi Wasada, Shigeo Nakamura, Yoshihiro Matsuno, Kazuo Oshimi, Tomohiro Kinoshita, Kunihiro Tsukasaki, Kensei Tobinai

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Concurrent chemoradiotherapy has become one of the standard management approaches for newly diagnosed localized nasal natural killer (NK)/T-cell lymphoma (NKTCL). Few data are available on the prognostic biomarkers of NKTCL among patients treated with concurrent chemoradiotherapy. To evaluate the prognostic significance of immunophenotypic biomarkers for patients treated with concurrent chemoradiotherapy, latent membrane protein 1 (LMP1), cutaneous lymphocyte antigen (CLA) and cell origin were examined in samples from 32 patients who were enrolled in the Japan Clinical Oncology Group 0211 trial and treated with concurrent chemoradiotherapy. LMP1 and CLA were positive in 66% (19/29) and 29% (9/31) of the cases examined, respectively. The median follow-up duration was 68 months (range, 61-94). The patients with LMP1-positive tumors showed a better overall survival (OS) than the patients with LMP1-negative tumors (hazard ratio, 0.240; 95% confidence interval [CI], 0.057-1.013; 80% CI, 0.093-0.615; P = 0.035). All five patients with LMP1-negative tumors who experienced disease progression died of lymphoma, and both patients with local failure had LMP1-negative tumors. There was no significant difference in OS according to CLA expression. A total of 27 (84%) cases were of NK-cell origin, two were of αβ T-cell origin and three were of γδ T-cell origin. In contrast to those with tumors of NK-cell origin, all five patients with NKTCL of T-cell origin were alive without relapse at the last follow up. Our results indicate that LMP1 expression is a favorable prognostic marker and suggest that a T-cell origin of the tumor may be a favorable prognostic marker for patients with localized NKTCL treated with concurrent chemoradiotherapy.

Original languageEnglish
Pages (from-to)1435-1441
Number of pages7
JournalCancer Science
Volume105
Issue number11
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Natural Killer T-Cells
T-Cell Lymphoma
Chemoradiotherapy
Biomarkers
Membrane Proteins
Natural Killer Cells
T-Lymphocytes
Neoplasms
Lymphocytes
Antigens
Skin
Confidence Intervals
Survival
Medical Oncology
Nose
Disease Progression
Lymphoma
Japan
Recurrence

Keywords

  • Clinical trial
  • Epstein-Barr virus
  • Extranodal NK/T-cell lymphoma
  • Latent membrane protein 1
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. / Yamaguchi, Motoko; Takata, Katsuyoshi; Yoshino, Tadashi; Ishizuka, Naoki; Oguchi, Masahiko; Kobayashi, Yukio; Isobe, Yasushi; Ishizawa, Kenichi; Kubota, Nobuko; Itoh, Kuniaki; Usui, Noriko; Miyazaki, Kana; Wasada, Izumi; Nakamura, Shigeo; Matsuno, Yoshihiro; Oshimi, Kazuo; Kinoshita, Tomohiro; Tsukasaki, Kunihiro; Tobinai, Kensei.

In: Cancer Science, Vol. 105, No. 11, 01.11.2014, p. 1435-1441.

Research output: Contribution to journalArticle

Yamaguchi, M, Takata, K, Yoshino, T, Ishizuka, N, Oguchi, M, Kobayashi, Y, Isobe, Y, Ishizawa, K, Kubota, N, Itoh, K, Usui, N, Miyazaki, K, Wasada, I, Nakamura, S, Matsuno, Y, Oshimi, K, Kinoshita, T, Tsukasaki, K & Tobinai, K 2014, 'Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy', Cancer Science, vol. 105, no. 11, pp. 1435-1441. https://doi.org/10.1111/cas.12526
Yamaguchi, Motoko ; Takata, Katsuyoshi ; Yoshino, Tadashi ; Ishizuka, Naoki ; Oguchi, Masahiko ; Kobayashi, Yukio ; Isobe, Yasushi ; Ishizawa, Kenichi ; Kubota, Nobuko ; Itoh, Kuniaki ; Usui, Noriko ; Miyazaki, Kana ; Wasada, Izumi ; Nakamura, Shigeo ; Matsuno, Yoshihiro ; Oshimi, Kazuo ; Kinoshita, Tomohiro ; Tsukasaki, Kunihiro ; Tobinai, Kensei. / Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. In: Cancer Science. 2014 ; Vol. 105, No. 11. pp. 1435-1441.
@article{47c88335d3c14252a33525ddc2d907a1,
title = "Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy",
abstract = "Concurrent chemoradiotherapy has become one of the standard management approaches for newly diagnosed localized nasal natural killer (NK)/T-cell lymphoma (NKTCL). Few data are available on the prognostic biomarkers of NKTCL among patients treated with concurrent chemoradiotherapy. To evaluate the prognostic significance of immunophenotypic biomarkers for patients treated with concurrent chemoradiotherapy, latent membrane protein 1 (LMP1), cutaneous lymphocyte antigen (CLA) and cell origin were examined in samples from 32 patients who were enrolled in the Japan Clinical Oncology Group 0211 trial and treated with concurrent chemoradiotherapy. LMP1 and CLA were positive in 66{\%} (19/29) and 29{\%} (9/31) of the cases examined, respectively. The median follow-up duration was 68 months (range, 61-94). The patients with LMP1-positive tumors showed a better overall survival (OS) than the patients with LMP1-negative tumors (hazard ratio, 0.240; 95{\%} confidence interval [CI], 0.057-1.013; 80{\%} CI, 0.093-0.615; P = 0.035). All five patients with LMP1-negative tumors who experienced disease progression died of lymphoma, and both patients with local failure had LMP1-negative tumors. There was no significant difference in OS according to CLA expression. A total of 27 (84{\%}) cases were of NK-cell origin, two were of αβ T-cell origin and three were of γδ T-cell origin. In contrast to those with tumors of NK-cell origin, all five patients with NKTCL of T-cell origin were alive without relapse at the last follow up. Our results indicate that LMP1 expression is a favorable prognostic marker and suggest that a T-cell origin of the tumor may be a favorable prognostic marker for patients with localized NKTCL treated with concurrent chemoradiotherapy.",
keywords = "Clinical trial, Epstein-Barr virus, Extranodal NK/T-cell lymphoma, Latent membrane protein 1, Radiotherapy",
author = "Motoko Yamaguchi and Katsuyoshi Takata and Tadashi Yoshino and Naoki Ishizuka and Masahiko Oguchi and Yukio Kobayashi and Yasushi Isobe and Kenichi Ishizawa and Nobuko Kubota and Kuniaki Itoh and Noriko Usui and Kana Miyazaki and Izumi Wasada and Shigeo Nakamura and Yoshihiro Matsuno and Kazuo Oshimi and Tomohiro Kinoshita and Kunihiro Tsukasaki and Kensei Tobinai",
year = "2014",
month = "11",
day = "1",
doi = "10.1111/cas.12526",
language = "English",
volume = "105",
pages = "1435--1441",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy

AU - Yamaguchi, Motoko

AU - Takata, Katsuyoshi

AU - Yoshino, Tadashi

AU - Ishizuka, Naoki

AU - Oguchi, Masahiko

AU - Kobayashi, Yukio

AU - Isobe, Yasushi

AU - Ishizawa, Kenichi

AU - Kubota, Nobuko

AU - Itoh, Kuniaki

AU - Usui, Noriko

AU - Miyazaki, Kana

AU - Wasada, Izumi

AU - Nakamura, Shigeo

AU - Matsuno, Yoshihiro

AU - Oshimi, Kazuo

AU - Kinoshita, Tomohiro

AU - Tsukasaki, Kunihiro

AU - Tobinai, Kensei

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Concurrent chemoradiotherapy has become one of the standard management approaches for newly diagnosed localized nasal natural killer (NK)/T-cell lymphoma (NKTCL). Few data are available on the prognostic biomarkers of NKTCL among patients treated with concurrent chemoradiotherapy. To evaluate the prognostic significance of immunophenotypic biomarkers for patients treated with concurrent chemoradiotherapy, latent membrane protein 1 (LMP1), cutaneous lymphocyte antigen (CLA) and cell origin were examined in samples from 32 patients who were enrolled in the Japan Clinical Oncology Group 0211 trial and treated with concurrent chemoradiotherapy. LMP1 and CLA were positive in 66% (19/29) and 29% (9/31) of the cases examined, respectively. The median follow-up duration was 68 months (range, 61-94). The patients with LMP1-positive tumors showed a better overall survival (OS) than the patients with LMP1-negative tumors (hazard ratio, 0.240; 95% confidence interval [CI], 0.057-1.013; 80% CI, 0.093-0.615; P = 0.035). All five patients with LMP1-negative tumors who experienced disease progression died of lymphoma, and both patients with local failure had LMP1-negative tumors. There was no significant difference in OS according to CLA expression. A total of 27 (84%) cases were of NK-cell origin, two were of αβ T-cell origin and three were of γδ T-cell origin. In contrast to those with tumors of NK-cell origin, all five patients with NKTCL of T-cell origin were alive without relapse at the last follow up. Our results indicate that LMP1 expression is a favorable prognostic marker and suggest that a T-cell origin of the tumor may be a favorable prognostic marker for patients with localized NKTCL treated with concurrent chemoradiotherapy.

AB - Concurrent chemoradiotherapy has become one of the standard management approaches for newly diagnosed localized nasal natural killer (NK)/T-cell lymphoma (NKTCL). Few data are available on the prognostic biomarkers of NKTCL among patients treated with concurrent chemoradiotherapy. To evaluate the prognostic significance of immunophenotypic biomarkers for patients treated with concurrent chemoradiotherapy, latent membrane protein 1 (LMP1), cutaneous lymphocyte antigen (CLA) and cell origin were examined in samples from 32 patients who were enrolled in the Japan Clinical Oncology Group 0211 trial and treated with concurrent chemoradiotherapy. LMP1 and CLA were positive in 66% (19/29) and 29% (9/31) of the cases examined, respectively. The median follow-up duration was 68 months (range, 61-94). The patients with LMP1-positive tumors showed a better overall survival (OS) than the patients with LMP1-negative tumors (hazard ratio, 0.240; 95% confidence interval [CI], 0.057-1.013; 80% CI, 0.093-0.615; P = 0.035). All five patients with LMP1-negative tumors who experienced disease progression died of lymphoma, and both patients with local failure had LMP1-negative tumors. There was no significant difference in OS according to CLA expression. A total of 27 (84%) cases were of NK-cell origin, two were of αβ T-cell origin and three were of γδ T-cell origin. In contrast to those with tumors of NK-cell origin, all five patients with NKTCL of T-cell origin were alive without relapse at the last follow up. Our results indicate that LMP1 expression is a favorable prognostic marker and suggest that a T-cell origin of the tumor may be a favorable prognostic marker for patients with localized NKTCL treated with concurrent chemoradiotherapy.

KW - Clinical trial

KW - Epstein-Barr virus

KW - Extranodal NK/T-cell lymphoma

KW - Latent membrane protein 1

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84911987396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911987396&partnerID=8YFLogxK

U2 - 10.1111/cas.12526

DO - 10.1111/cas.12526

M3 - Article

C2 - 25181936

AN - SCOPUS:84911987396

VL - 105

SP - 1435

EP - 1441

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -